EA202192296A1 - Терапевтическое применение дулаглутида - Google Patents

Терапевтическое применение дулаглутида

Info

Publication number
EA202192296A1
EA202192296A1 EA202192296A EA202192296A EA202192296A1 EA 202192296 A1 EA202192296 A1 EA 202192296A1 EA 202192296 A EA202192296 A EA 202192296A EA 202192296 A EA202192296 A EA 202192296A EA 202192296 A1 EA202192296 A1 EA 202192296A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dulaglutide
therapeutic use
cardiovascular
diagnosed
cardiovascular disease
Prior art date
Application number
EA202192296A
Other languages
English (en)
Inventor
Джеффри С. Рисмейер
Дэвид Брэдли Вудворд
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA202192296A1 publication Critical patent/EA202192296A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к способам снижения риска серьезных нежелательных сердечно-сосудистых явлений у пациентов с сахарным диабетом 2 типа (СД2), имеющих множественные факторы риска сердечно-сосудистых заболеваний без диагностированного сердечно-сосудистого заболевания или диагностированное сердечно-сосудистое заболевание, включающим введение дулаглутида в качестве агониста рецепторов глюкагоноподобного пептида-1 (GLP-1).
EA202192296A 2019-04-05 2019-11-04 Терапевтическое применение дулаглутида EA202192296A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962829717P 2019-04-05 2019-04-05
PCT/US2019/059631 WO2020204998A1 (en) 2019-04-05 2019-11-04 Therapeutic uses of dulaglutide

Publications (1)

Publication Number Publication Date
EA202192296A1 true EA202192296A1 (ru) 2022-01-21

Family

ID=68732046

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192296A EA202192296A1 (ru) 2019-04-05 2019-11-04 Терапевтическое применение дулаглутида

Country Status (15)

Country Link
US (2) US11890325B2 (ru)
EP (1) EP3946428A1 (ru)
KR (2) KR20230132627A (ru)
CN (2) CN113631181A (ru)
AU (2) AU2019439626B2 (ru)
BR (1) BR112021017315A2 (ru)
CA (2) CA3177693A1 (ru)
EA (1) EA202192296A1 (ru)
IL (1) IL285765A (ru)
MA (1) MA55467A (ru)
MX (1) MX2021012177A (ru)
SG (1) SG11202109892UA (ru)
TW (2) TWI804692B (ru)
WO (1) WO2020204998A1 (ru)
ZA (1) ZA202106250B (ru)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0879279A4 (en) 1996-02-06 2000-07-12 Lilly Co Eli DIABETE TREATMENT
DK1294757T3 (da) 2000-06-16 2007-03-19 Lilly Co Eli Glucagonlignende peptid 1-analoger
DK1724284T3 (da) 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusionsproteiner
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
WO2005000892A2 (en) 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins
WO2006068910A1 (en) 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations
AU2008275180A1 (en) 2007-07-10 2009-01-15 Eli Lilly And Company GLP-1-Fc fusion protein formulation
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2014270882B2 (en) 2013-05-22 2019-03-14 Zensun (Shanghai) Science & Technology, Co. Ltd. Extended release of neuregulin for treating heart failure
EP3027691A4 (en) 2013-07-29 2017-04-19 SG Ventures Pty Limited Metallic pigments and method of coating a metallic substrate
MA43684A (fr) 2016-03-04 2018-11-28 Novo Nordisk As Liraglutide utilisé dans le traitement de maladies rénales
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
ES2847168T5 (es) * 2016-07-29 2024-02-20 Kowa Co Métodos para prevenir acontecimientos cardiovasculares en poblaciones dislipidémicas de riesgo residual
US20200171129A1 (en) 2017-06-01 2020-06-04 Eli Lilly And Company Therapeutic uses of dulaglutide

Also Published As

Publication number Publication date
EP3946428A1 (en) 2022-02-09
US11890325B2 (en) 2024-02-06
WO2020204998A1 (en) 2020-10-08
MA55467A (fr) 2022-02-09
US20220202908A1 (en) 2022-06-30
AU2022291679A1 (en) 2023-02-02
KR20210134713A (ko) 2021-11-10
CN114732897A (zh) 2022-07-12
SG11202109892UA (en) 2021-10-28
TW202400213A (zh) 2024-01-01
AU2019439626B2 (en) 2022-10-13
CN113631181A (zh) 2021-11-09
IL285765A (en) 2021-10-31
AU2019439626A1 (en) 2021-09-16
ZA202106250B (en) 2023-04-26
CA3056663A1 (en) 2020-10-05
TW202103729A (zh) 2021-02-01
TWI804692B (zh) 2023-06-11
KR20230132627A (ko) 2023-09-15
CA3177693A1 (en) 2020-10-05
MX2021012177A (es) 2021-11-04
US20240139287A1 (en) 2024-05-02
CA3056663C (en) 2022-10-18
BR112021017315A2 (pt) 2021-11-16

Similar Documents

Publication Publication Date Title
MY197569A (en) Gip/glp1 co-agonist compounds
Apaijai et al. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin‐resistant rats
MX2019006429A (es) Compuestos novedosos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip.
EA202090392A3 (ru) Соединения-коагонисты гип и гпп-1
WO2017009236A3 (en) New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists
EA200701469A1 (ru) Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшаемых увеличением уровня glp-1 крови
EA201892383A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
BR112021020071A2 (pt) Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
CL2020003237A1 (es) Proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) (divisional de la solicitud no. 201801695)
AR119471A1 (es) Compuestos agonistas de gipr
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
JP2014504588A5 (ru)
RU2013155474A (ru) Ликсисенатид и метформин для лечения диабета типа 2
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
JP2017520509A5 (ru)
EA202192296A1 (ru) Терапевтическое применение дулаглутида
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
JOP20220153A1 (ar) نظائر الإنكرتين واستخداماتها
NZ602583A (en) Methods of using diacerein as an adjunctive therapy for diabetes
Ciardullo et al. Changes in long-term glycemic control and performance indicators in a cohort of type 2 diabetic patients cared for by general practitioners: findings from the “Modena Diabetes Project”
JP2015517534A5 (ru)
CO2020002117A2 (es) Métodos para el tratamiento de enfermedades relacionadas con tnfα